Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ICM ADX-2191 injection
ICM ADX-2191 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Induction/Consolidation/Maintenance (ICM) ADX-2191 injection | EXPERIMENTAL | - |
| Monthly ADX-2191 injection | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ICM ADX-2191 injection | DRUG | Following the development of lymphomatous vitreous cells in at least one eye, subjects will follow ICM dosing with ADX-2191 intravitreal injections twice weekly for four weeks, followed by weekly for eight weeks, for a total of sixteen injections. |
| Monthly ADX-2191 injection | DRUG | Following the development of lymphomatous vitreous cells in at least one eye, subjects will dose monthly with ADX-2191 intravitreal injections for a total of three injections. Sham injections will be performed for those visits during which ADX-2191 is not injected, for a total of thirteen sham injections. |
Inclusion Criteria: 1. 21 years old or older; of any gender 2. Biopsy proven primary vitreoretinal lymphoma 3. Presence of lymphomatous vitreous cells at the Screening Visit and/or any eye that has been vitrectomized to confirm the diagnosis of primary vitreoretinal lymphoma 4. Willingness to parti...
ICM ADX-2191 is an investigational small molecule being developed for the treatment of primary vitreoretinal lymphoma, a rare cancer of the eye. It is currently in Phase 3 clinical development and has not been approved by the FDA.
ICM ADX-2191 is being developed by Aldeyra Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALDX. The company is conducting a Phase 3 clinical trial of the drug in the United States.
ICM ADX-2191 is in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Priority Review and Orphan Drug designations by the FDA for the treatment of primary vitreoretinal lymphoma.
ICM ADX-2191 is being evaluated in a Phase 3 clinical trial with the identifier NCT07402876. This randomized, double-blind, active-controlled study is recruiting approximately 20 adult patients with primary vitreoretinal lymphoma in the United States.
Yes, ICM ADX-2191 is also known as ICM ADX-2191 injection. Both names refer to the same investigational drug being developed by Aldeyra Therapeutics for primary vitreoretinal lymphoma.